BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26574845)

  • 1. Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes.
    Hussein YR; Ducie JA; Arnold AG; Kauff ND; Vargas-Alvarez HA; Sala E; Levine DA; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):404-9. PubMed ID: 26574845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.
    Howitt BE; Hanamornroongruang S; Lin DI; Conner JE; Schulte S; Horowitz N; Crum CP; Meserve EE
    Am J Surg Pathol; 2015 Mar; 39(3):287-93. PubMed ID: 25581732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
    Reyes MC; Arnold AG; Kauff ND; Levine DA; Soslow RA
    Mod Pathol; 2014 Oct; 27(10):1405-11. PubMed ID: 24577588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution.
    Okoye E; Euscher ED; Malpica A
    Am J Surg Pathol; 2016 May; 40(5):627-35. PubMed ID: 26900814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.
    Ritterhouse LL; Nowak JA; Strickland KC; Garcia EP; Jia Y; Lindeman NI; Macconaill LE; Konstantinopoulos PA; Matulonis UA; Liu J; Berkowitz RS; Nucci MR; Crum CP; Sholl LM; Howitt BE
    Mod Pathol; 2016 Aug; 29(8):893-903. PubMed ID: 27150160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-Generation Sequencing of Tubal Intraepithelial Carcinomas.
    McDaniel AS; Stall JN; Hovelson DH; Cani AK; Liu CJ; Tomlins SA; Cho KR
    JAMA Oncol; 2015 Nov; 1(8):1128-32. PubMed ID: 26181193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
    Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
    J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.
    Djordjevic B; Malpica A
    Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases.
    Gallotta V; Conte C; D'Indinosante M; Capoluongo E; Minucci A; De Rose AM; Ardito F; Giuliante F; Di Giorgio A; Zannoni GF; Fagotti A; Margreiter C; Scambia G; Ferrandina G
    Eur J Surg Oncol; 2019 Nov; 45(11):2096-2102. PubMed ID: 31227342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
    Soslow RA; Han G; Park KJ; Garg K; Olvera N; Spriggs DR; Kauff ND; Levine DA
    Mod Pathol; 2012 Apr; 25(4):625-36. PubMed ID: 22193042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.
    Vos S; Elias SG; van der Groep P; Smolders YH; van Gils CH; van Diest PJ
    Am J Surg Pathol; 2018 Sep; 42(9):1262-1272. PubMed ID: 29979200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
    Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
    Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
    George J; Alsop K; Etemadmoghadam D; Hondow H; Mikeska T; Dobrovic A; deFazio A; ; Smyth GK; Levine DA; Mitchell G; Bowtell DD
    Clin Cancer Res; 2013 Jul; 19(13):3474-84. PubMed ID: 23633455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA mutations and risk of uterine cancer.
    Tanday S
    Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397041
    [No Abstract]   [Full Text] [Related]  

  • 19. Subsequent breast and high grade serous carcinomas after risk-reducing salpingo-oophorectomy in BRCA mutation carriers and patients with history of breast cancer.
    Straub MM; Podoll MB; David SN; Wiesner GL; Desouki MM
    Ann Diagn Pathol; 2018 Oct; 36():28-30. PubMed ID: 30055521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
    Dong F; Davineni PK; Howitt BE; Beck AH
    Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.